drugset
Drugs / RTS,S/AS02A
last change Aug 2024 re-read 3 minutes ago

RTS,S/AS02A

Vaccine

Developed for
malaria
Investigated by
GlaxoSmithKline

Trials 1

today NCT00197041 · Ph 2
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00197041 Jul 2003 → Apr 2005 malaria GlaxoSmithKline Completed Met primary

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as RTS,S/AS02(A) “RTS,S/AS02(A) vaccine is immunogenic and induces long-lasting anti-circumsporozoite antibodies, persisting at least 42 months after immunization.” PMID 21443960 ↗ Apr 2011
1

NCT00197041 ↗
Modality Vaccine “The RTS,S malaria vaccine is currently recommended for children aged 5-6 months in regions with moderate-to-high Plasmodium falciparum transmission.” PMID 39127054 ↗ Aug 2024
Route Intramuscular “Administered Intramuscularly According to a 0, 1 and 2 Month Vaccination Schedule” NCT00197041 ↗